Team

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/09\/Eran.png","name":"Eran Eden, PhD","position":"Co-founder and CEO, Board of Directors","content":"Eran has been the CEO of MeMed since its inception in 2009, leading it from an idea to rapidly growing company. He has 18 years of combined business and academic experience pioneering the development of cutting-edge multidisciplinary technologies that synergize data-science \u0026 machine learning, molecular biology and clinical applications. Eran co-founded several highly funded international consortia the mission of which is to develop, clinically validate and commercialize novel technologies for diagnosing patients with infectious diseases and inflammatory disorders. He holds a B.Sc. in Computer Engineering, B.A. in Biology, and M.Sc. in Computer Science (all Cum Laude) from the Technion, Israel Institute of Technology, and a Ph.D. in Systems Biology from the Weizmann Institute of Science, where he was also a lecturer of Data Mining. Eran is co-author of over 100 granted patents and pending applications and over 25 peer-reviewed publications and is the recipient of multiple awards including the prestigious GE and Science Prize for Promising Life Scientists.","linkedin":"https:\/\/www.linkedin.com\/in\/eran-eden-5695743\/","twitter":"https:\/\/twitter.com\/eraneden"}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/kfir.jpg","name":"Dr. Kfir Oved","position":"Co-Founder, Chief Technology Officer \u0026 Chairman of Board of Directors","content":"Kfir has over 15 years of combined industry and academic experience, leading interdisciplinary and multicultural teams combining Applied Immunology, Biochemistry, Engineering, Big Data, and Industrial Design in multiple clinical applications. Kfir co-founded MeMed and serves as its Chief Technology Officer and Chairman of the Board. He led the development and clinical validation of the entire MeMed technology suite from initial concept to development completion, including MeMed BV­® and MeMed Key®. He holds a B.A. in Biology (Summa Cum Laude), B.Sc. in Medicine (Magna Cum Laude), Ph.D. in Molecular Immunology, and six years training at the Technion-Institute of Technology School of Medicine. He is the co-author of 83 granted and pending patents, the author of 16 peer-reviewed publications, and the recipient of multiple research excellence awards, including the prestigious Gutwirth Excellence Award and the Wolf Award for research students, and was listed as one of the top 25 voices in Precision Medicine for 2019.","linkedin":"https:\/\/www.linkedin.com\/in\/kfir-oved-96b2201b\/","twitter":"https:\/\/twitter.com\/Kfir_Oved"}

{"image":false,"name":"Prof. Itamar Shalit","position":"Clinical Advisor","content":"Prof. Shalit is an Associate Professor in Pediatrics, Sackler Faculty of Medicine, Tel-Aviv University and a world authority in Pediatric Infectious Diseases. Prof. Shalit served as the Director of the Infectious Diseases Unit and Director General of Schneider Children\u0027s Hospital, tertiary care, referral pediatric center, for the entire state of Israel. He also served as the Director General of Carmel Hospital, the Chairman of the Israeli Society for Infectious Diseases, and as a member of the Scientific Advisory Boards of leading pharma and biotech companies including Bioline Rx, Teva Innovative Ventures, NasVax and Integra Ltd. Prof. Shalit is an active member of several national committees of the Israeli Ministry of Health among them the Advisory Board on Infectious Diseases and Immunization, Polio Eradication Committee, and the Epidemics Management Team. He was awarded the Certificate of Appreciation Declaration by the World Health Organization for outstanding efforts and success in poliomyelitis eradication in Israel. Prof. Shalit holds an MD from the Sackler School of Medicine, Tel-Aviv University and a MPA (Master in Public Administration) from the Kennedy School of Government at the Harvard University. He is the author of more than 90 peer reviewed scientific papers and currently serves as the CEO of the Galilee Biomedical Research Administration.","linkedin":"","twitter":""}

{"image":false,"name":"Dr. Louis Bont","position":"Clinical Advisor","content":"Louis Bont, MD, PhD, is a Pediatrician Infectiologist at the University Medical Center Utrecht, The Netherlands. His research activities focus on viral respiratory tract infections, particularly RSV bronchiolitis. He leads the Utrecht RSV Research Group. Dr. Bont received several awards including the European Society of Pediatric Infectious Diseases (ESPID) Fellowship Award. He has published 70 papers in peer-reviewed journals and is the chairman of the international Bronchiolitis Academy training program for pediatricians, the Global Expert Meeting on respiratory viruses (GEM) and the Training of Upcoming Leaders in Paediatric Sciences (TULIPS) in The Netherlands. He holds an ESPID membership. Dr. Bont earned his medical degree from the University of Amsterdam, The Netherlands and completed a residency in pediatrics at Victoria Hospital in Blackpool, United Kingdom; St. Antonius Hospital in Nieuwegein, The Netherlands; and Wilhelmina Children’s Hospital, University Medical Center in Utrecht, The Netherlands.","linkedin":"","twitter":""}

{"image":false,"name":"Prof. Paul Feigin","position":"Statistics Advisor","content":"Paul Feigin is Professor of Statistics and the Senior Executive VP of the Technion, Israel Institute of Technology. He is an authority on statistical design and analysis of genomic studies, and clinical studies. Prof. Feigin has served as a statistician regulatory consultant for many companies, working on clinical study protocol design and statistical analysis. He has extensive experience in strategic preparation for regulatory submission and communication with regulatory agencies and notified bodies. Prof. Feigin served as Dean of the Faculty of Industrial Engineering and Management at the Technion, as president of the Israel Statistical Association, and he is currently an elected fellow of the Institute of Mathematical Statistics and of the International Statistical Institute. Prof. Feigin published over 50 scientific papers and has been a visiting professor at world-class institutes including Berkeley, Cornell University, Stanford University and others.","linkedin":"https:\/\/www.linkedin.com\/in\/paul-feigin-3b535b1\/?originalSubdomain=il","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/brandes.png","name":"Mr. Hanina Brandes","position":"Board Member","content":"Mr. Brandes is the founding and managing partner of Naschitz-Brandes, one of the leading law firms in Israel. Mr. Brandes has advised on some of Israel’s largest and most complex international commercial transactions. His clients include Israel’s leading public and private companies. Mr. Brandes is the chairman of the High-tech committee of the Israeli Bar, a member of the Board of Governors of Tel-Aviv University, as well as a member of the Board of Trustees and the Board of Directors of Tel-Aviv Museum of Art.","linkedin":"","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/hibbard.png","name":"Mr. Chris Hibberd","position":"Board Member","content":"Chris Hibberd has more than 20 years of industry experience, leading global organizations that deliver high medical value products. Chris serves as CEO and Executive Chairman of Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier. Prior to Nucleix, he was CEO and Co-Founder of Astute Medical, where he led the organization and securing of funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Mr. Hibberd previously served as Senior Vice President of Corporate Development at Biosite and earlier in his career, Chris was a manager at The Boston Consulting Group and a development engineer at Albright and Wilson Americas. He has an MBA from the University of Western Ontario and a B.A.Sc. in chemical engineering from the University of Toronto.","linkedin":"https:\/\/www.linkedin.com\/in\/chris-hibberd-a2b78a6b\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Team-Male.png","name":"Mr. Peter Neustadter","position":"Board Member","content":"Mr. Neustadter was an early investor and consultant to Mobileye and served on its Board of Directors as the non-executive presiding officer until its sale to Intel in 2017. Peter was President and CEO of Durawool Inc., which developed and became the leading manufacturer of non-asbestos fibers for the automotive industry. He is currently Managing Director of Iat holdings LLC which invests in Israeli automotive technologies and International Automotive Trading, a financial advisory company. Today he is active in several startups and philanthropic institutions.","linkedin":"","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/terry.png","name":"Mr. Patrick F. Terry","position":"Board Member","content":"Mr. Terry is a social entrepreneur who has co-founded a dozen life science organizations in the last 20 years and has been called the godfather of applied genomics and personalized medicine. The organizations co-founded by Mr. Terry include innovative philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. In 2000, he co-founded Genomic Health, Inc. (NASDAQ: GHDX), a pioneering personalized medicine company. Mr. Terry has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery all over the world. He has received many honors and awards in the business and scientific communities internationally. He has dedicated his career to advancing a patient-centered perspective in research, product development, and translational medicine. He is active internationally with strategic management and financing of stratified medicine companies for numerous clinical indications and technologies.","linkedin":"https:\/\/www.linkedin.com\/in\/patrick-f-terry-93589\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Zhang2.png","name":"Mr. Patrick Zhang","position":"Board Member","content":"Patrick Zhang is an investor at Horizons Ventures, where he primarily covers biotechnology, healthcare and fintech investments, and manages related portfolio companies for Horizons. He was trained as a chemical engineer and worked in a variety of organizations across industries including power utilities, financial services and investment management. Prior to Horizons, Patrick was an investment banker with Morgan Stanley providing financial advisory services on capital raising and cross-border M\u0026amp;A to his clients. Mr. Zhang received his BS degree in Chemical Engineering from UCLA and MBA from Columbia Business School.","linkedin":"https:\/\/www.linkedin.com\/in\/patrick-zhang-0b133215\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Kfir-emmer.jpg","name":"Kfir Emmer","position":"Chief Financial Officer","content":"Kfir has more than a decade of experience in the fields of finance and accounting. Prior to joining MeMed’s team, Kfir, previously acted as the Financial Controller at Viola Ventures, Israel\u0027s leading venture capital firm with over $1.3 billion assets under management. Prior to that, Kfir held the position of senior auditor at PwC, specializing in auditing biotech companies. Kfir has extensive experience in private placements, cash management, strategic planning, deal analysis, accounting, and financial operations management. Kfir is a Certified Public Accountant and also holds a B.A. in Accounting and Economics and an MBA (Financial Management), both from the Tel Aviv University.","linkedin":"https:\/\/www.linkedin.com\/in\/kfir-emmer-39602775\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Troy.png","name":"Troy Boutelle, MBA","position":"General Manager MeMed USA, Vice President, Commercial North America","content":"Troy has 20 years of experience in commercial leadership roles at life science companies in the US. Prior to joining MeMed, Troy was Vice President, Sales \u0026amp; Marketing at Eurofins-Viracor where he oversaw significant growth and multiple product launches. Troy’s previous positions include Commercial Leader at Thermo Fisher Scientific, where he led the commercial team for the Americas Microbiology business, managing a portfolio of over 4,000 products. Troy also serves as an adjunct professor at Bentley University where he teaches a course on sales and marketing.","linkedin":"https:\/\/www.linkedin.com\/in\/troy-boutelle-mba-50171510\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2022\/10\/Ofer.png","name":"Ofer Chen, MD","position":"Vice President, Medical","content":"Ofer is an M.D, with a master\u0027s degree in public administration from Harvard University. Ofer brings over 20 years of experience as a practicing physician (internal medicine, oncology), and over a decade\u0027s experience of leadership roles in public hospitals and in community health care. Among other roles, he was department head at Maccabi healthcare and deputy director of Assuta Hospital in Ashdod. Ofer had a key position in the establishment of the hospital. In his last position, he was VP clinical development at a Clew Medical – an Israeli medical AI startup.","linkedin":"","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Tanya.png","name":"Dr. Tanya Gottlieb","position":"Vice President, Scientific Affairs","content":"Tanya has over 20 years of experience in academia and biotech, specializing in building and cultivating international collaborations and securing non-dilutive financing. Before joining MeMed, Tanya was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative start-up developing a universal flu vaccine, where she initiated collaborations with the National Institute of Health (US) and European Commission. Prior to that, Tanya served as an independent consultant for key opinion leaders in Israel and Europe, helping to maximize their impact in the field and win awards. Tanya conducted her postdoctoral research at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. Tanya holds a B.A. in Natural Sciences and Ph.D. from Cambridge University, UK and an MBA from the Technion, Israel. She is the co-author of over 20 peer reviewed publications and the recipient of multiple awards, including the prestigious Royal Society (UK)-Israel Academy Fellowship.","linkedin":"https:\/\/www.linkedin.com\/in\/tanya-gottlieb-91b5b131\/","twitter":"https:\/\/twitter.com\/tanya2go"}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Will.png","name":"Will Harris","position":"Vice President, Global Marketing","content":"Will has over 15 years of senior Marketing and Product Management leadership experience for disruptive technologies in the diagnostics and robotics industries. Prior to joining MeMed, Will served as a Principal of Technical Product Management and Single Threaded Leader at Amazon Robotics, responsible for development and deployment of the first robotic package manipulation program deployed at Amazon network scale. Before Amazon, Will served as the Director of Product Management at T2 Biosystems responsible for product roadmap, go-to-market strategy, and commercialization of the first, FDA cleared direct-from-blood sepsis test. Before his work at T2, Will was the Global Marketing Manager for Clinical Toxicology at Waters. Will holds a Bachelor of Arts in Economics from Hamilton College.","linkedin":"https:\/\/www.linkedin.com\/in\/will-harris-b9909b3\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Efrat.jpg","name":"Dr. Efrat Hartog-David","position":"Vice President, Regulatory Affairs \u0026 Quality Assurance","content":"Efrat has over a decade of experience in Quality Assurance, Clinical and Regulatory Affairs. She has managed product lifecycle quality and regulatory submissions for clearances of numerous medical devices globally including in the US, EU, and China. Before joining MeMed, Efrat was Regulatory Affairs Manager at GE Healthcare responsible for leading and executing the global regulatory strategy for the Nuclear Medicine business. As part of her role at GE Healthcare she led a team responsible for providing leadership and guidance on global compliance, developing global regulatory strategies and plans, and preparing regulatory submissions and worldwide registrations. Efrat has also served as Regulatory Affairs specialist at Philips Healthcare, where she was the regulatory lead for programs aimed at introduction of new product, and played a key role in internal and external audits. Prior to that, Efrat served as a consultant for a wide range of medical device companies, focusing on clinical study design, quality system management, and regulatory strategy development and execution. Efrat holds a B.Sc. and Ph.D. in Biotechnology and Food Engineering from the Technion, Haifa, Israel.","linkedin":"https:\/\/www.linkedin.com\/in\/efrat-hartog-david-1b490a4\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/hila.jpg","name":"Hila Hershkovitz","position":"Vice President, Human Resources","content":"Hila has over 18 years of experience in senior Human Resources (HR) leadership roles with fast growing tech companies in various stages. Prior to joining MeMed, Hila served as HR Business Partner for EMEA region at Amdocs, and for the Operation Innovation Unit where she oversaw all global HR activities. Prior to that, Hila worked with startups, including Flash Networks and Correlsense, and was responsible for the global HR strategy. Hila holds a B.A. in Social Work from Tel Aviv University and an MBA from Bar-Ilan University.","linkedin":"https:\/\/www.linkedin.com\/in\/hila-hershkovitz-306b7114\/","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Team-Male.png","name":"Haim Regev","position":"Vice President, Commercial EMEA","content":"Haim has over 20 years of experience in leadership roles at MedTech companies. Prior to joining MeMed, Haim was CEO at Siemens Healthineers Israel where he led a talented team of Sales \u0026 Marketing, Customer Service, Clinical Application and Project Management. The company made significant growth and became the market leader in its fields. Haim was also a team member of the global VC group scouting the Israeli innovation ecosystem and building partnerships and investments. Prior to that, Haim served as a territory manager at Boston Scientific Israel.","linkedin":"","twitter":""}

{"image":"https:\/\/www.me-med.com\/wp-content\/uploads\/2021\/10\/Oren.jpg","name":"Dr. Oren Zarchin","position":"Vice President, Research \u0026 Development","content":"Oren is a highly experienced leader of Product Development in global corporations, with more than 20 years of business and academic experience in the medical and semiconductors industries. In his latest role, Oren served as Vice President, Product Development and executive management at Mazor Robotics LTD. Following Mazor\u0027s acquisition by Medtronic PLC, he served as Vice President, Product Development at Medtronic, leading Research \u0026amp; Development and Product Management. Prior to Medtronic, Oren held various leadership positions at Philips Healthcare where he led multi-disciplinary Research \u0026amp; Development teams and product platforms in the US and Israel. Oren has a Ph.D. in Physics from the Weizmann Institute of Science, M.Sc. (summa cum laude) in Physics and B.Sc. (cum laude) in Computer Science and Physics from Tel-Aviv University. He holds 15 patents and is the co-author on multiple publications.","linkedin":"https:\/\/www.linkedin.com\/in\/orenzar\/","twitter":""}